Business, energy, technology, markets and global industry news from Business News Today

GSK plc

PharmaDeviceNews GSK plc
ViiV Healthcare’s two-drug Dovato regimen matched the three-drug Biktarvy regimen for viral suppression at Week 48 in the head-to-head VOGUE HIV study. Representative image.
Pharma & Biotech

ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data

ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.

Read More
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Pharma & Biotech

Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin

China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More
Representative image: GSK’s $1 billion SiranBio deal highlights how oligonucleotide therapies such as SA030 could open a new front in metabolic disease research by targeting visceral fat biology beyond conventional obesity drugs.
Pharma & Biotech

GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery

GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.

Read More
Pharma & Biotech

GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy

GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.

Read More
Pharma & Biotech

ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance

ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.

Read More
Representative image: GSK to acquire RAPT Therapeutics for $2.2 billion, strengthening its immunology pipeline with ozureprubart, a long-acting anti-IgE therapy in development for food allergy protection. The asset could shift standard care by enabling quarterly dosing.
Pharma & Biotech

Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?

GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from

Read More
Representative image: A respiratory specialist discusses lung health and biologic treatment options with a COPD patient, aligned with our coverage of GSK’s Nucala approval for eosinophilic COPD in China.
Pharma & Biotech

GSK secures China NMPA approval for Nucala in eosinophilic COPD, targeting hospitalisation risk

GSK PLC (LSE/NYSE: GSK) has received regulatory approval from the National Medical Products Administration of China for Nucala (mepolizumab) as an add-on maintenance therapy for adults with eosinophilic chronic obstructive pulmonary disease (COPD) inadequately controlled on inhaled triple therapy. The greenlight marks a strategic respiratory expansion for GSK in the world’s largest COPD market and

Read More
Representative image illustrating the rising focus on U.S. drug pricing reform, as pharmaceutical companies like GSK move to expand access to asthma and COPD medicines through lower costs and direct purchasing models.
Pharma & Biotech

GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs

GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies

Read More